Krill oil supplier Neptune Technologies & Bioressources Inc. (Laval, QC) has been awarded health claims from Health Canada (Ottawa, ON) for its NKO krill oil.
Krill oil supplier Neptune Technologies & Bioressources Inc. (Laval, QC) has been awarded health claims from Health Canada (Ottawa, ON) for its NKO krill oil. The company made the announcement two weeks ago.
The claims provided for NKO krill oil-relating to cardiovascular health inflammation, and women's health-are as follows:
Cardiovascular Health:
"Helps to reduce the levels of LDL cholesterol (in conjunction with conventional statin therapy): 2 softgels (1g) per day."
"Helps to increase the levels of HDL cholesterol (in conjunction with conventional statin therapy): 2 softgels (1g) per day."
"Helps to reduce the levels of triglycerides (in conjunction with conventional statin therapy): 4 softgels (2g) per day."
Inflammation:
"Helps to reduce C-reative protein levels, a clinical marker of inflammation: 1 softgel (0.5g) per day."
"Helps to reduce pain associated with osteoarthritis: 1 softgel (0.5g) per day."
Women's Health:
"Helps to relieve symptoms of premenstrual syndrome (PMS)."
"Helps to relieve symptoms of dysmenorrhea: 4 softgels (2g) per day."
For more information, visit Neptune Technologies and Bioressources Inc.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.